Reuters logo
Germany's Bayer to launch three new Xarelto trials
August 29, 2014 / 2:05 PM / 3 years ago

Germany's Bayer to launch three new Xarelto trials

FRANKFURT, Aug 29 (Reuters) - Germany’s Bayer said it plans to launch three new studies to add more uses for its anti-clotting drug Xarelto, one of its top five new medicines.

Xarelto, which competes with Bristol-Myers Squibb and Pfizer’s Eliquis pill in stroke prevention, reached sales of $1.7 billion in the 12 months through June, with analysts estimating annual sales could rise to more than $9.5 billion by 2020.

Two new Phase III trials are to test Xarelto, jointly developed with U.S. peer Johnson & Johnson, on patients with embolic stroke of undetermined source and peripheral artery disease, Bayer said in a statement on Friday.

The third new study is a Phase II trial designed to evaluate Xarelto for long-term prevention in patients who have suffered an acute coronary syndrome. If the study is successful, a Phase III study will follow, Bayer said. (1 US dollar = 0.7592 euro) (Reporting by Maria Sheahan; Editing by Jonathan Gould)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below